Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Alabama Site-of-Service P…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - alabamaPolicy PH-90001

    Mandatory Site of Service Management Policy

    Customize your policy alerts

    Sign up for blue cross blue shield - alabama Policy PH-90001 alerts

    Get alerted when Policy PH-90001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs site-of-care requirements and prior authorization for select provider-administered infused specialty medications for Blue Cross Blue Shield - Alabama members participating in the Provider‑Administered Drug Program; affects providers ordering/administrating the listed infused specialty drugs.

    Policy Summary
    Payerblue cross blue shield - alabama
    PolicyMandatory Site of Service Management Policy
    Policy CodePolicy PH-90001
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewAug 13, 2024
    Next Review Date
    Key ActionObtain prior authorization and document intended place of treatment for all drugs in the Mandatory Site of Service program.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2021-01-01program effective date
    08/13/2024last review
    multiplelisted infused specialty drug codes

    Coverage Criteria

    Initial site-of-service coverage criteria

    Covered when ALL of the following are met

    Program applicability: Member is in a group or individual plan participating in the Provider-Administered Drug Program with Mandatory Site of Service and has home healthcare benefits

    New utilizers on or after 2021-01-01 and current utilizers at prior authorization renewal on or after 2021-01-01 are subject

    Prior authorization is obtained for the requested drug and the intended place of treatment is documented

    All drugs in the Mandatory Site of Service Management require prior authorization; additional criteria may be reviewed based on administration site; members identified as receiving listed drugs in a hospital outpatient setting will be referred to Prime Therapeutics' Infusion Referral Center (IRC)

    IRC assessment and transition: If member is receiving a listed specialty drug in a hospital outpatient setting, IRC referral occurs to determine whether transition to an alternate site of care (home infusion or infusion suite) is appropriate

    IRC will confirm criteria for transition and home infusion providers will obtain necessary nursing precertifications when required

    Exceptions (hospital outpatient medically necessary)

    Administration in a hospital outpatient setting may be considered medically necessary if ANY of the following exception conditions are met and documented

    Immediate need for hospital-level services: Potential changes in clinical condition require immediate access to hospital services (emergency resuscitation equipment and personnel, inpatient admission or intensive care) due to risk of sudden life‑threatening changes

    Examples provided in policy; documentation must be submitted

    Higher risk for adverse reaction from co-morbid conditions: Member has co-morbid conditions (e.g., renal dysfunction, cardiopulmonary disease, physical/cognitive impairment) that increase risk of adverse reaction

    Documentation of the co-morbid condition, potential adverse reaction, and clinical rationale must be submitted

    History of anaphylaxis to related infusion therapy: Prior anaphylaxis to infusion therapy with a related pharmacologic or biologic agent despite standard premedication

    Documentation of the prior anaphylactic reaction must be submitted

    Select infused specialty medications included in the Site of Service program are subject to change. The policy list may be updated to add currently available infused specialty medications; prescribers will be notified in advance per provider contract terms. Specific exclusions or drugs not listed are outside the scope of this policy unless formally added to the program.

    Drugs and Codes in Scope

    Drugs in scope (group 1)HCPCSCovered
    J3262ACTEMRA / tocilizumab
    J0791ADAKVEO / crizanlizumab-tmca
    J1931ALDURAZYME / laronidase
    J1554ASCENIV / intravenous immune globulin
    Q5121AVSOLA / infliximab-axxq
    J0490BENLYSTA / belimumab
    J0597BERINERT / C1 esterase inhibitor
    J1556BIVIGAM / intravenous immune globulin
    J1786CEREZYME / imiglucerase
    J0717CIMZIA / certolizumab pegol
    1–10 of 20
    1/2
    Drugs in scope (group 2)HCPCSCovered
    J1569GAMMAGARD LIQUID / intravenous immune globulin
    J1566GAMMAGARD S/D, CARIMUNE NF / intravenous immune globulin
    J1561GAMMAKED / intravenous immune globulin
    J1557GAMMAPLEX / intravenous immune globulin
    J1561GAMUNEX / intravenous immune globulin
    J1599IMMUNE GLOBULIN / intravenous immune globulin
    Q5103INFLECTRA / infliximab-dyyb
    J2840KANUMA / sebelipase alfa
    J0221LUMIZYME / alglucosidase alfa
    J1458NAGLAZYME / galsulfase
    1–10 of 20
    1/2
    Drugs in scope (group 3)HCPCSCovered
    Q5104RENFLEXIS / infliximab-abda
    J9312RITUXAN (non-oncology diagnosis only) / rituximab
    Q5119RUXIENCE (non-oncology diagnosis only) / rituximab-pvvr
    J1299SOLIRIS / eculizumab
    J3241STELARA = TEPEZZA / teprotumumab-trbw
    J2356STELARA = TEZSPIRE / tezepelumab-ekko
    J1746STELARA = TROGARZO / ibalizumab-uiyk
    Q5115STELARA = TRUXIMA (non-oncology diagnosis only) / rituximab-abbs
    J2323STELARA = TYSABRI / natalizumab
    J1303STELARA = ULTOMIRIS / ravulizumab-cwvz
    1–10 of 13
    1/2

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    All drugs in the Mandatory Site of Service Management require prior authorization. As part of the prior authorization review, information about the intended place of treatment will be obtained and additional criteria may be reviewed based on where the drug will be administered. Failure to obtain required prior authorization or failure to provide necessary documentation may result in denial of coverage.

    • Prior authorization required for all drugs in the Mandatory Site of Service program.
    • Intended place of treatment will be collected during prior authorization review.
    • Additional criteria may be applied depending on the planned site of administration.
    Note

    Site-of-Service Referral Process

    Members identified as receiving listed specialty drugs in a hospital outpatient setting will be referred to Prime Therapeutics' Infusion Referral Center (IRC). The IRC will review the case and confirm whether the member can be transitioned to an alternate place of treatment (e.g., home infusion provider or infusion suite). When transition is required, the selected home infusion provider must obtain any necessary nursing precertifications as specified by the member's benefits.

    Background

    The purpose of the Mandatory Site of Service program is to ensure infusions of select specialty medications occur in the most cost‑effective, clinically appropriate location. The program directs members receiving listed provider‑administered infused specialty drugs toward alternative sites of care (for example, home infusion or infusion centers) when appropriate, while allowing hospital outpatient administration only when medically necessary and documented. Changes to the list of drugs included in the program may occur; prescribers will receive advance notification as specified in provider contracts.

    Definitions

    Mandatory Site of Service program — definition
    Program definitionA component of the Provider‑Administered Drug Program that directs members to use the most cost‑effective, clinically appropriate infusion setting for select specialty medications and requires prior authorization for listed drugs.
    Primary goalEnsure infusion occurs in the most cost‑effective, clinically appropriate location (e.g., home or infusion center vs hospital outpatient) when clinically appropriate.
    Prior authorization requirementPrior authorization is required for drugs in the Mandatory Site of Service program and will document intended place of treatment; referrals may be made during PA processing.
    Referral processMembers receiving listed specialty drugs in a hospital outpatient setting will be referred to an Infusion Referral Center to assess transition to home infusion or an infusion suite when appropriate.

    Initial Therapy / Site-of-Service Requirements

    Initial therapy/site-of-service requirement

    Initial and new utilizers

    New utilizer requirement: New utilizers on or after 2021-01-01 are subject to the Mandatory Site of Service program and must have prior authorization

    Program effective date January 1, 2021; current users become subject upon prior authorization renewal on or after that date

    Step Therapy

    StepRequirementProvider action
    1Members identified as receiving listed specialty drugs in a hospital outpatient setting will be referred to Prime Therapeutics' Infusion Referral Center (IRC)Document intended place of treatment during prior authorization; cooperate with IRC referral and provide clinical information as requested to support transition to an alternate site (home infusion or infusion suite).
    2IRC will assess whether criteria are met to transition the member to an alternate place of treatment (e.g., home infusion provider or infusion suite)Provide timely clinical documentation and any required nursing precertifications to the designated home infusion provider when transition is approved.

    Site of Care Rules

    Note

    Use the most cost‑effective, clinically appropriate infusion site

    Members must receive infusion therapy at the most cost‑effective, clinically appropriate location; hospital outpatient administrations will be referred to the IRC for evaluation of transition to home infusion or an infusion suite when appropriate.

    • Program effective date: members initiating medications on or after 2021-01-01 are subject to the requirement; current users are subject at PA renewal on/after that date.
    Policy Summary
    Payerblue cross blue shield - alabama
    PolicyMandatory Site of Service Management Policy
    Policy CodePolicy PH-90001
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewAug 13, 2024
    Next Review Date
    Key ActionObtain prior authorization and document intended place of treatment for all drugs in the Mandatory Site of Service program.
    SourceLink
    On This Page
    Coverage CriteriaDrugs and Codes in ScopeProvider Actions & RequirementsBackgroundDefinitionsInitial Therapy / Site-of-Service RequirementsStep TherapySite of Care Rules
    Intolerable fluid overload or unstable renal function: Member has intolerable fluid overload, including impaired or unstable renal function

    Documentation required

    No home caregiver with acute impairment: Acute mental status or cognitive changes or physical impairment AND no home caregiver available

    Both factors must be documented

    Unstable vascular access: Vascular access is not stable with significant documented venous access issues

    Submission of documentation required

    Recent bone marrow transplant: Member received a bone marrow transplant within the prior 6 months and requires enhanced monitoring at a specialized facility

    Documentation of the procedure/treatment must be submitted

    Lack of access to home or in-network infusion: No access to home infusion or in-network Ambulatory Infusion Suite AND nearest office-based provider exceeds travel distance to the current hospital outpatient center

    Documentation of access and travel distance must be submitted

    Unsafe home environment: Home is deemed unsafe for infusion (e.g., excessive pets, aggressive animals)

    Requires written documentation; next site of care would be provider office

    Program effective / new utilizer date
    Program effective dateProgram effective January 1, 2021; applies to members initiating listed medications on or after 2021-01-01.
    New utilizer applicabilityNew utilizers of listed medications on or after 2021-01-01 are subject to the Mandatory Site of Service program.
    Current utilizer applicabilityMembers currently using listed medications become subject to the program upon prior authorization renewal on or after 2021-01-01.
    • Referral to Prime Therapeutics' Infusion Referral Center for members receiving select specialty drugs in a hospital outpatient setting.
    • IRC confirms eligibility for transition to home infusion or infusion suite.
    • Home infusion provider responsible for nursing precertifications when required.
    Documentation Required

    Exception Documentation Requirements

    Documentation supporting medical necessity is required to support exceptions to the Mandatory Site of Service Policy when outpatient/hospital administration is requested. Submit clear clinical rationale and relevant supporting evidence at the time of prior authorization or during case assessment. Missing or insufficient documentation may lead to denial of the exception request.

    • Clinical rationale explaining why outpatient/hospital administration is medically necessary.
    • Documentation of co-morbid conditions and how they increase risk of adverse reaction (e.g., renal dysfunction, cardiopulmonary disease).
    • Records documenting prior anaphylaxis or severe reaction to related infusion therapy, if applicable.
    • Evidence of intolerable fluid overload or unstable renal function, if applicable.
    • Documentation of acute mental status/cognitive changes or physical impairment and lack of home caregiver, when claimed.
    • Evidence of unstable vascular access or significant venous access issues.
    • Clinical history of cardiopulmonary conditions that increase risk of severe adverse reactions.
    • Documentation of bone marrow transplant within prior 6 months, when applicable.
    • Proof that member lacks access to home infusion or in-network ambulatory infusion suite and that travel to the nearest office-based provider exceeds travel to the hospital outpatient center.
    • Documentation that the home environment is unsafe for infusion (e.g., excessive pets, unsafe conditions) with justification for office-based administration.
    Denial Risk

    Prior Authorization Requirement and Potential Denial

    Prior authorization is required for all drugs in the Mandatory Site of Service program. If prior authorization is not obtained or required exception documentation is not submitted, the authorization request or claim may be denied.

    • All drugs in the Mandatory Site of Service program require prior authorization — denials possible if not obtained.
    • Exception reviews may occur during prior authorization or at any point during case assessment; timely submission of documentation is required.